Gene therapy offers the potential to deliver therapeutic proteins to a target region, and is a promising treatment for Parkinson disease. A new open-label study testing ProSavin®, which encodes three rate-limiting enzymes required for dopamine biosynthesis, showed favourable safety and efficacy results, but its therapeutic potential awaits confirmation in double-blind trials.
